Navicent Health Adopts iCAD’s Breast Cancer Detection and Therapy Solutions to Enhance Patient Care
Prominent medical center is first in the United States to expand breast health offerings with iCAD’s PowerLook Tomo Detection solution and Xoft System
NASHUA, N.H., and MACON, Ga., (Tuesday, October 30, 2018) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its complete suite of leading-edge breast health innovations including PowerLook® Tomo Detection, a radiology workflow solution built on artificial intelligence, and the Xoft® Axxent®Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer using intraoperative radiation therapy (IORT), are now available at The Medical Center, Navicent Health, the second largest hospital in Georgia. Navicent Health, based in Macon, Ga., is now the first health system in the country to offer iCAD’s most advanced solutions for both the detection and treatment of breast cancer.
The hospital is also the first in the state to offer IORT with the Xoft System. The comprehensive technologies are available at Navicent Health’s Peyton Anderson Cancer Center and mark an important advancement for the more than 8,000 women who will be diagnosed with breast cancer this year in Georgia. The new offerings also coincide with the hospital’s “Paint the Town Pink” community campaign for National Breast Cancer Awareness Month in October.
“Our adoption of iCAD’s premier products for the detection and treatment of breast cancer underscores our commitment to elevating health and well-being through compassionate, personalized care,” said Dr. Ninfa M. Saunders, FACHE, President and CEO, Navicent Health. “With the addition of PowerLook Tomo Detection and Xoft IORT, our providers are armed with proven technological advancements that offer our patients valuable, life-changing benefits.”
“iCAD is committed to delivering revolutionary technology that supports healthcare professionals in providing quality care to patients worldwide,” said Ken Ferry, CEO, iCAD. “We are pleased to partner with Navicent Health, making it possible for clinicians at this nationally recognized center to improve their breast cancer detection and treatment programs that will have a lasting impact in their community.”
Advanced Artificial Intelligence Technology
PowerLook Tomo Detection is an innovative cancer detection solution for digital breast 3D tomosynthesis (DBT) that incorporates artificial intelligence to optimize workflow efficiencies and support decision making. The technology utilizes a trained, deep learning algorithm that automatically analyzes each tomosynthesis slice, providing radiologists with a single, highly-sensitive, enhanced image that is used to easily navigate these expansive datasets. PowerLook Tomo Detection is clinically proven to optimize radiologists’ image reading and interpretation by reducing read-time by an average of 29.2 percent. The solution is the first and only U.S. Food and Drug Administration (FDA) approved concurrent-read cancer detection solution for DBT, is CE marked, and is currently available in the U.S., Europe and Canada. iCAD’s PowerLook breast health solutions support more than 3,500 healthcare facilities worldwide.
Innovative Radiation Therapy Treatment
Xoft IORT is a radiation treatment that uses a miniaturized X-ray source to deliver a full course of targeted radiation inside the body, directly within the tumor cavity at the time of breast conserving surgery (lumpectomy). IORT allows radiation oncologists and breast cancer surgeons to work together to offer appropriately selected patients an option to avoid the need for six to seven weeks of post-operative external beam radiation therapy (EBRT). A recent study found IORT to be the preferred method of treatment as compared to EBRT, due to significant cost savings, reduced radiation exposure and improved quality of life. The Xoft System is cleared by the FDA, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancer and gynecological cancers. It has been used to successfully treat more than 15,000 patients worldwide.
ARPR, on behalf of iCAD, Inc.
Paul Barren, (855) 300-8209
Megan Allen, (478) 550-4380
Jeremy Feffer, (212) 915-2568
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
About Navicent Health
Navicent Health was incorporated on November 17, 1994, as a nonprofit corporation whose primary purpose is to coordinate The Medical Center, Navicent Health and other affiliated entities in their mission of providing a comprehensive continuum of high quality, reasonably priced healthcare services to the region. Navicent Health has 970 beds for medical, surgical, rehabilitation and hospice purposes. The health system includes The Medical Center, Navicent Health, a nationally recognized tertiary teaching hospital; Beverly Knight Olson Children’s Hospital, Navicent Health, the region’s only dedicated pediatric hospital; Navicent Health Baldwin and Medical Center of Peach County, Navicent Health, both rural hospitals; Rehabilitation Hospital, Navicent Health, the region’s oldest and most experienced rehabilitation provider; Pine Pointe, Navicent Health, which provides palliative and hospice care in homes and in its facility; Carlyle Place, Navicent Health, the area’s first continuing care retirement community; Navicent Health Foundation, the philanthropic arm of Navicent Health; as well as diagnostic and home care services. For more information, please visit www.navicenthealth.org.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2017, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.